Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS-PH
2009-011169-98Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary hypertension (PH) and idiopathic pulmonary fibrosis (IPF) comparing Ambrisentan with Placebo (2 arms). Primary endpoint: Change from baseline in 6-minute walk distance. Started Aug 2009; status: terminated.
02
Drugs
ambrisentan
03
Conditions
pulmonary hypertension (PH)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2009-011169-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011169-98.